Abstract: Recombinantly produced hepatitis GB Virus (HGBV) amino acid sequences useful for a variety of diagnostic and therapeutic applications, kits for using the HGBV amino acid sequences and antibodies which specifically bind to HGBV. Also provided are methods for producing antibodies, polyclonal or monoclonal, from the HGBV recombinantly produced amino acid sequences.
Type:
Grant
Filed:
April 19, 1996
Date of Patent:
December 5, 2000
Assignee:
Abbott Laboratories
Inventors:
Tami J. Pilot-Matias, Thomas P. Leary, John N. Simons, Robert J. Carrick, Teresa K. Surowy, Suresh M. Desai, George J. Dawson, Anthony Scott Muerhoff, Isa K. Mushahwar
Abstract: Hepatitis GB Virus (HGBV) nucleic acid and amino acid sequences useful for a variety of diagnostic and therapeutic applications, kits for using the HGBV nucleic acid or amino acid sequences, HGBV immunogenic particles, and antibodies which specifically bind to HGBV. Also provided are methods for producing antibodies, polyclonal or monoclonal, from the HGBV nucleic acid or amino acid sequences.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
April 18, 2000
Assignee:
Abbott Laboratories
Inventors:
John N. Simons, Tami J. Pilot-Matias, George J. Dawson, George G. Schlauder, Suresh M. Desai, Thomas P. Leary, Anthony Scott Muerhoff, James Carl Erker, Sheri L. Buijk, Isa K. Mushahwar
Abstract: This invention provides a novel mammalian expression system that is capable of generating high levels of expressed hepatitis C virus (HCV) proteins which have previously proved difficult to express due to their non-secretory properties. In particular, the invention provides a plasmid for the expression of the HCV second envelope protein (E2) designated p577. This plasmid encodes a recombinant protein comprising the immunoglobulin signal peptide and amino acids 388-664 of the HCV E2 glycoprotein. This unique expression system produces high levels of HCV proteins that are properly processed, glycosylated, and folded.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
February 1, 2000
Assignee:
Abbott Laboratories
Inventors:
Gregory F. Okasinski, Verlyn G. Schaefer, Thomas S. Suhar, Richard R. Lesniewski
Abstract: Hepatitus GB Virus (HGBV) nucleic acid and amino acid sequences useful for a variety of diagnostic and theraeutic applications, kits for using the HGBV nucleic acid or amino acid sequences, HGBV immunogenic particles, and antibodies which specifically bind to HGBV. Also provided are methods for producing antibodies, polyclonal or monoclonal, from the HGBV nucleic acid or amino acid sequences.
Type:
Grant
Filed:
April 6, 1995
Date of Patent:
November 9, 1999
Assignee:
Abbott Laboratories
Inventors:
John N. Simons, Tami J. Pilot-Matias, George J. Dawson, George G. Schlauder, Suresh M. Desai, Thomas P. Leary, Anthony Scott Muerhoff, Sheri L. Buijk, James Carl Erker, Isa K. Mushahwar
Abstract: Mammalian expression systems for the production of HCV fusion proteins. Such expression systems provide high yields of HCV fusion proteins, and enable the development of diagnostic and therapeutic reagents which contain glycosylated structural antigens and also allow for the isolation of the HCV etiological agent.
Type:
Grant
Filed:
September 18, 1996
Date of Patent:
December 29, 1998
Assignee:
Abbott Laboratories
Inventors:
James M. Casey, Suzanne L. Bode, Billy J. Zeck, Julie Yamaguchi, Donald E. Frail, Suresh M. Desai, Sushil G. Devare
Abstract: Chemiluminescent electron-rich aryl-substituted 1,2-dioxetane compounds are disclosed in which the aryl group is poly-substituted with suitable electron-donating groups such that the light-emitting pattern of the molecule results in a very high luminescent count, thus providing for a sensitive and precise assay for haptens, analytes, polynucleotides and the like. These substituted aryl-containing 1,2-dioxetane compounds can be used as direct labels in an immunoassay or when derivatized with an appropriate leaving group, can be used as a substrate for a enzyme immunoassay. The unusual chemiluminescence of the compounds allows the timing of the luminescent reaction to be exactly controlled.
Abstract: Improved methods for detecting antibodies in test samples. The improvement comprises uses CKS-fusion proteins specific for the antibodies in assays such as screening assays, competitive assays, confirmatory assays and immunodot assays. Test kits which contain these CKS-fusion proteins useful in such assays also are provided.
Type:
Grant
Filed:
June 23, 1992
Date of Patent:
June 21, 1994
Assignee:
Abbott Laboratories
Inventors:
Timothy J. Bolling, Wlodzimierz Mandecki, Sushil G. Devare, James M. Casey, Suresh M. Desai